| Value | ₹1,400 Cr |
|---|
BSE filing, NSE: JUBLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹923.80
- Market cap
- ₹14,714 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 41.8×Sector 48.7×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Board Meeting Date
Jubilant Pharmova has scheduled a board meeting for November 13, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing is a Regulation 29 advance intimation only.
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova Ltd has issued a Postal Ballot Notice seeking shareholder approval for the private placement issuance of Non-Convertible Debentures.
Jubilant Pharmova Other Announcement
Jubilant Pharmova Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Jubilant Pharmova Credit Rating
Jubilant Pharmova received an [ICRA]AA+ (Stable) rating from ICRA for its proposed non-convertible debentures. This confirms the credit assessment for the upcoming debt instrument.
Jubilant Pharmova Debt & Borrowing: ₹800 Cr
Jubilant Pharmova board approved NCD issuance up to ₹800 crore on private placement basis. Postal ballot also sought for NCD authorization up to ₹2,500 crore.
- Value
- ₹800.0 Cr
- Execution
- Upto five years from the Deemed Date of Allotment
Jubilant Pharmova Capacity Expansion: ₹633.1 Cr Investment
Jubilant Pharmova's Radiopharma business will invest CAD 94.5 million (approx. ₹633 Crore) to expand production capacity at its Kirkland facility, aiming to double RUBY-FILL® production.
- Value
- ₹633.1 Cr
- production capacity
- 2.0 times
Other credit rating announcements
All →Borosil Renewables Credit Rating
Borosil Renewables had its bank loan rating upgraded to IND AA-/Stable/IND A1+ by India Ratings. Proposed bank facilities of Rs 450 million were assigned the same rating.
Singer India Credit Rating
Singer India's Rs.45 Crore bank facilities were re-rated by CRISIL. Long-term stayed BBB-/Stable while the short-term rating was upgraded to Crisil A3+.
Bondada Engineering Credit Rating
CRISIL upgraded credit ratings for five subsidiaries of Bondada Engineering to A/Stable or A-/Stable. The upgrade reflects strong financials and supports the group's lender credibility.
20 Microns Credit Rating
CRISIL reaffirmed 20 Microns' bank loan ratings at A/Stable and A1 on ₹117 crore facilities. Ratings remain unchanged from prior assessment.
Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.